APYX Overview

Public Offering Announcement: Apyx Medical Corporation has priced its underwritten public offering of 2,762,431 shares of common stock at $3.62 per share, with the offering expected to close on or about November 19, 2025.

Use of Proceeds: The company plans to use the net proceeds from the offering for working capital and general corporate purposes.

Underwriter Details: Lucid Capital Markets is the sole book-running manager for the offering, which includes a 45-day option for the underwriter to purchase an additional 414,365 shares.

Company Overview: Apyx Medical specializes in surgical aesthetics, offering innovative products like Renuvion and the AYON Body Contouring System, supported by extensive clinical documentation.

Public Offering Announcement: Apyx Medical Corporation has announced the commencement of an underwritten public offering of its common stock, subject to market conditions, with no assurance on the completion or terms of the offering.

Role of Lucid Capital Markets: Lucid Capital Markets is serving as the sole book-running manager for the public offering, which is being made under a previously filed shelf registration statement with the SEC.

Company Overview: Apyx Medical specializes in surgical aesthetics, offering innovative products like Renuvion and the AYON Body Contouring System, which are designed to enhance surgical procedures and patient outcomes.

Forward-Looking Statements Caution: The company has issued a cautionary statement regarding forward-looking statements, highlighting various risks and uncertainties that could affect its financial performance and the success of the public offering.

FDA Submission: Apyx Medical Corporation has submitted a new 510(k) premarket notification to the FDA to expand the AYON Body Contouring System's label to include power liposuction.

AYON System Features: The AYON system, already FDA-cleared, combines fat removal, tissue contraction, contouring, and electrosurgical functions in one platform, with plans to activate new functionality upon FDA clearance.

Company Announcement: Apyx Medical Corporation will participate in the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, where CEO Charlie Goodwin and CFO Matt Hill will engage in a fireside chat and hold one-on-one meetings with investors.

Product Overview: Apyx Medical specializes in advanced energy technology, offering products like Renuvion® and AYON Body Contouring System™, which utilize helium plasma and radiofrequency technology for cosmetic and surgical applications, supported by over 90 clinical publications.

Renuvion at Miami Swim Week: Apyx Medical's Renuvion will showcase real patient transformations at Miami Swim Week, emphasizing the empowerment and confidence gained through their treatments for loose skin.

Innovative Technology: Renuvion utilizes helium plasma and radiofrequency energy to provide effective body contouring solutions, supported by extensive clinical documentation, positioning it as a trusted option in cosmetic surgery.